HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals has completed the development of a clinical-grade assay for FLT3 protein expression, a significant step towards starting Phase I clinical trials for its HEMO-CAR-T candidate at MD Anderson Cancer Center. The company, specializing in treatments for cancers and viral diseases, aims to use the assay to identify and recruit appropriate patients for its upcoming trials, which will later expand to the University of Pennsylvania Medical Center. This progress could lead to a new treatment for acute myeloid leukemia (AML), a disease with currently limited survival rates.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
